Previous close | 4.7100 |
Open | 4.7100 |
Bid | 0.0000 x 800 |
Ask | 0.0000 x 1300 |
Day's range | 4.7000 - 4.9361 |
52-week range | 3.8800 - 13.5200 |
Volume | |
Avg. volume | 109,325 |
Market cap | 117.234M |
Beta (5Y monthly) | 0.45 |
PE ratio (TTM) | N/A |
EPS (TTM) | -2.3200 |
Earnings date | 08 Nov 2023 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 33.00 |
Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today announced financial results for the quarter ended September 30, 2023, and highlighted recent corporate progress.
Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, announced today participation in the Jefferies London Healthcare Conference, taking place November 14-16, 2023, in London. Dave Lennon, Ph.D., President and CEO, will participate in a fireside chat on Tuesday, November 14, 2023, at 8:30 am GMT.
Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that it will host a conference call and live webcast on Wednesday, November 8, 2023 at 8:30 am ET (5:30 am PT) to report third quarter 2023 financial results and provide an operational update.